New HIV vaccine trial aims to boost immune control
NCT ID NCT07530198
First seen Apr 17, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This early-stage trial tests a therapeutic DNA vaccine called ICVAX in 22 adults with HIV who are stable on antiretroviral therapy (ART). The goal is to see if the vaccine is safe and can boost the body's immune response against HIV. Participants receive four vaccine injections over 16 weeks and are monitored for about 8 months. The study compares three different delivery methods to find the best way to give the vaccine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Chinese University of Hong Kong Phase 1 Clinical Trial Centre at Prince of Wales Hospital
RECRUITINGShatin, New Territories, 00000, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.